+86 137 2013 4139
+86 137 2013 4139
| CAS: | 2641998-63-0 | Cat No: | JKN05263 | Purity: | 98% |
Note: All products of the company are for scientific research only, and do not provide products and services for any individual
Elironrasib (RMC-6291) marks a significant advancement in drug development by enabling direct targeting of the active, GTP-bound form of KRAS G12C, a molecular target long regarded as inaccessible to therapeutic intervention.
The resulting ternary assembly effectively blocks downstream oncogenic signaling and drives tumor regression across a range of preclinical cancer models carrying KRAS G12C mutations. Through a structure-based medicinal chemistry optimization program, elironrasib was identified as a highly potent, orally available, and selective covalent inhibitor of RAS(ON) G12C. Elironrasib is currently under evaluation in multiple Phase 1 clinical studies (NCT05462717, NCT06128551, NCT06162221), where early clinical findings suggest meaningful activity in patients who have developed resistance to first-generation KRAS G12C inhibitors that target the inactive RAS state.
Product Description
| CAS | 2641998-63-0 | Cat No | JKN05263 | |
| Name | Elironrasib | |||
| Synonyms | RMC-6291 | |||
| Smiles | CCN1C2=C3C=C(C=C2)N4CCO[C@H](C4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC=C6)[C@H](C)OC)(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)C7(CCN(CC7)C(=O)C#CC(C)(C)N(C)C)F | |||
| Chemical Name | (3S)-N1-[N-[[1-[4-(Dimethylamino)-4-methyl-1-oxo-2-pentyn-1-yl]-4-fluoro-4-piperidinyl]carbonyl]-N-methyl-L-valyl-3-[4-[(2R)-1-ethyl-3-(3-hydroxy-2,2-dimethylpropyl)-2-[2-[(1S)-1-methoxyethyl]-3-pyridinyl]-1H-indol-5-yl]-2-morpholinyl]-L-alanyl]hexahydro-3-pyridazinecarboxylic acid (3→2)-lactone | |||
| Formula | C55H78FN9O8 | MWt | 1012.26 | |
| Purity | 98% | Storage | Store at 4--8℃ | |
| Description | RMC-6291 is an orally available, highly potent KRASG12C(ON) inhibitor with anticancer and antitumor activity that acts through spatial blockade of RAS effector binding.RMC-6291 blocks ERK signaling and induces apoptosis in KRASG12C-mutant H358 cells. | |||
Product Documents
Menu
Contact Us
Tel: +86 137 2013 4139
E-mail: orders@jknbiochem.com
Add.:Room 2120, Office Building 2, No.1 Baisha Fifth Road, Hongshan District, Wuhan City, Hubei Province, China
Get In Touch
Get In Touch
